Generic Vimpat Availability

Vimpat is a brand name of lacosamide, approved by the FDA in the following formulation(s):

VIMPAT (lacosamide - solution;intravenous)

  • Manufacturer: UCB INC
    Approval date: October 28, 2008
    Strength(s): 200MG/20ML (10MG/ML) [RLD]

VIMPAT (lacosamide - solution;oral)

  • Manufacturer: UCB INC
    Approval date: April 20, 2010
    Strength(s): 10MG/ML [RLD]

VIMPAT (lacosamide - tablet;oral)

  • Manufacturer: UCB INC
    Approval date: October 28, 2008
    Strength(s): 50MG, 100MG, 150MG, 200MG [RLD]

Has a generic version of Vimpat been approved?

No. There is currently no therapeutically equivalent version of Vimpat available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vimpat. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Amino acid derivative anticonvulsant
    Patent 5,654,301
    Issued: August 5, 1997
    Inventor(s): Kohn; Harold L. & Watson; Darrell
    Assignee(s): Research Corporation Technologies, Inc.
    The present invention relates to compounds of the formula ##STR1##
    Patent expiration dates:
    • August 5, 2014
      ✓ 
      Patent use: METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • August 5, 2014
      ✓ 
      Patent use: METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Anticonvulsant enantiomeric amino acid derivatives
    Patent RE38551
    Issued: July 6, 2004
    Inventor(s): Harold; Kohn
    Assignee(s): Research Corporation Technologies, Inc.
    The present invention is directed to a compound in the R configuration about the asymmetric carbon in the following formula: pharmaceutical compositions containing same and the use thereof in treating CNS disorders in animals.
    Patent expiration dates:
    • March 17, 2022
      ✓ 
      Patent use: METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • March 17, 2022
      ✓ 
      Patent use: METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE
      ✓ 
      Drug substance
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • October 28, 2013 - NEW CHEMICAL ENTITY

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web3)